Drew Bawcombe, MD
Retina Specialist · Deerfield Beach, FLNPI 1801004932
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 26.2% of the total. That places this record below the midpoint for retina specialist clinicians in FL, where the typical reported total is $2,986.
Across 70 payments — averaging $38.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$702
- Johnson & Johnson Surgical Vision, Inc.$516
- Apellis Pharmaceuticals, Inc.$401
- Genentech USA, Inc.$268
- AbbVie$259
- Mallinckrodt Hospital Products Inc.$164
- plus $366 from 8 others
Across 4 payments — averaging $499,893 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2M
What the payments were for
- Food & beverage$2,676100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 28 | $702 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $516 |
| Apellis Pharmaceuticals, Inc. | 8 | $401 |
| Genentech USA, Inc. | 8 | $268 |
| AbbVie(2 entities) | 8 | $259 |
| Mallinckrodt Hospital Products Inc. | 3 | $164 |
| Rayner Intraocular Lenses Limited | 1 | $121 |
| NEW World Medical,inc. | 1 | $92 |
| Alimera Sciences, Inc. | 1 | $48 |
| Harrow Eye, LLC | 1 | $29 |
| Novartis | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$247
- VERITAS Vision System$247
- Tecnis IOL$145
- ACTHAR$130
- OZURDEX$123
- VUITY$123
- EYLEA HD$122
- RayOne EMV$121
- RayOne Spheric$121
- RayOne Aspheric$121
- VABYSMO$100
How this compares
$2,676 in reported general payments places this provider in the 45th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 343 | $830,019 |
| VabysmoFaricimab-Svoa | 161 | $439,443 |
| Eylea HdAflibercept | 94 | $299,433 |
| SyfovrePegcetacoplan/Pf | 62 | $148,785 |
| LucentisRanibizumab | 13 | $37,824 |
| LumiganBimatoprost | 63 | $25,447 |
| AvastinBevacizumab | 14 | $12,917 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $11,944 |
| RhopressaNetarsudil Mesylate | 22 | $9,048 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $7,867 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $5,125 |
| Prednisolone Acetate | 96 | $4,127 |
| Alphagan PBrimonidine Tartrate | 20 | $3,687 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 52 | $2,558 |
| Brimonidine Tartrate | 89 | $2,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $702 | $1,129,452437 claims |
| Genentech USA, Inc.Vabysmo | $268 | $439,443161 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $401 | $148,78562 claims |
| AbbVieLumigan, Combigan, Alphagan P | $259 | $41,078120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Deerfield Beach
- Shailesh GuptaDeerfield Beach$23K
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Timothy MurraySouth Miami$133K
- Adiel SmithAventura$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.